Instrumento Inactivo

Otros idiomas Stealth BioTherapeutics Corp

Acciones

MITO

US85789A1051

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Stealth BioTherapeutics Corp Highlights Opportunities and Challenges in Ultra-Rare Disease Drug Development at World Orphan Drug Congress USA	14/06/23
Stealth BioTherapeutics Announces Positive End-Of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration	12/06/23
Stealth Biotherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide	30/05/23
Stealth BioTherapeutics Corp Announces Completion of Merger	17/11/22
Stealth BioTherapeutics Corp(NasdaqGM:MITO) dropped from NASDAQ Composite Index	16/11/22
J. Wood Capital Advisors LLC and Morningside Venture (I) Investments Limited completed the acquisition of 22.5293% stake in Stealth BioTherapeutics Corp.	16/11/22
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis	02/11/22
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)	01/11/22
Stealth BioTherapeutics Corp Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis	01/11/22
Stealth BioTherapeutics : Investor Presentation - October 2022	14/10/22
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders	10/10/22
Stealth BioTherapeutics Announces Departure of Chief Financial Officer	03/10/22
Stealth BioTherapeutics Chief Financial Officer Departs	03/10/22
Stealth BioTherapeutics Announces Departure of Chief Financial Officer	30/09/22
Stealth BioTherapeutics Corp Announces Departure of Robert Weiskopf as Chief Financial Officer	30/09/22
Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events	15/09/22
Stealth BioTherapeutics Corp Enters Definitive Agreement for Going Private Transaction	02/08/22
Stealth BioTherapeutics Corp Agrees to Go Private; Shares Jump	01/08/22
Stealth BioTherapeutics : Enters Definitive Agreement for Going Private Transaction - Form 6-K	01/08/22
STEALTH BIOTHERAPEUTICS ANNOUNCES RECEIPT OF NON-COMPLIANCE NOTICE FROM NASDAQ	12/07/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Stealth BioTherapeutics Corp

Acciones

MITO

US85789A1051

Otros idiomas

Filtros